Marlborough biomanufacturing campus sold for $125M
Courtesy | National Resilience
92 Crowley Drive, Marlborough, shown under construction, was sold for $125 million.
A biomanufacturing facility at 92 Crowley Drive in Marlborough was sold by San Diego biotech National Resilience, Inc. to Canadian real estate giant Oxford Properties Group of Toronto on Thursday, according to the Middlesex South Registry of Deeds.
The property was last sold to Resilience in April for $11 million by a corporation affiliated with Marlborough developer First Colony Development Co. Resilience then undertook a project to add 35,000 square feet to the facility.
Although it sold the property, Resilience has given no indication it plans to leave the site in Marlborough it just built. The California company, founded in 2020, is building a network of high-tech facilities in order to manufacture drugmakers’ medicines quickly, safely, and at scale. The site head of the Marlborough facility, Natalie Friel, was named a 2022 WBJ Outstanding Woman in Business.
LFB USA, a unit of France’s LFB Group, purchased the site in 2015 from First Colony for $2.6 million to develop a 70,000-square-foot facility on the site. The drug manufacturer then sold the site back to a First Colony LLC in 2018 for $4.5 million before Resilience bought it.
Oxford Properties, the new owner of the property, had previously purchased a 113,000-square-foot biomanufacturing facility at 33 New York Ave. in Framingham for $95 million in 2020. That facility is fully leased to Swiss biotech CRISPR Therapeutics AG and Replimune of Woburn, according to Oxford Properties’ website.
In addition to the Resilience property Oxford is building a 140,000-square-foot biomanufacturing facility at 149 Hayes Memorial Drive in Marlborough, expected to be complete by the end of 2022.
WBJ Web Partners
Most Recent
Most Recent
0 Comments